Induction of robust diabetes resistance and prevention of recurrent type 1 diabetes following islet transplantation by gene therapy

Journal of Immunology

Volumn 179, Issue 10, 2007, Pages 6762-6769

  Tian, Chaorui ^a   Ansari, Mohammed Javeed I ^a   Paez Cortez, Jesus ^a   Bagley, Jessamyn ^a   Godwin, Jonathan ^a   Donnarumma, Michela ^a   Sayegh, Mohamed H ^a   Iacomini, John ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; BASILIXIMAB; INSULIN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; B7 ANTIGEN; DIFFERENTIATION ANTIGEN; HLA ANTIGEN CLASS 2; I A(B) ANTIGEN, MOUSE; I-A(B) ANTIGEN, MOUSE; INTERLEUKIN 2 RECEPTOR ALPHA; MEMBRANE PROTEIN; PD 1 ANTIGEN, MOUSE; PD-1 ANTIGEN, MOUSE; PDCD1LG1 PROTEIN, MOUSE; PEPTIDE; UNCLASSIFIED DRUG;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BETA CHAIN; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENE THERAPY; HEMATOPOIETIC CELL; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT DISEASE; RETROVIRUS; VIRAL GENE DELIVERY SYSTEM; ANIMAL; AUTOTRANSPLANTATION; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION; GENETIC TRANSDUCTION; GENETICS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOLOGY; ISOGRAFT; METABOLISM; MOUSE MUTANT; PANCREAS ISLET; T LYMPHOCYTE; TRANSPLANTATION TOLERANCE;

ALLELES; ANIMALS; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; GENE EXPRESSION; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; PEPTIDES; RETROVIRIDAE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, ISOGENEIC;

EID: 38449092694     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.10.6762     Document Type: Article

References (64)

1. Froud, T., C. Ricordi, D. A. Baidal, M. M. Hafiz, G. Ponte, P. Cure, A. Pileggi, R. Poggioli, H. Ichii, A. Khan, et al. 2005. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am. J. Transplant. 5: 2037-2046.
2. Shapiro, A. M., J. R. Lakey, E. A. Ryan, G. S. Korbutt, E. Toth, G. L. Warnock, N. M. Kneteman, and R. V. Rajotte. 2000. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343: 230-238.
3. Ryan, E. A., J. R. Lakey, R. V. Rajotte, G. S. Korbutt, T. Kin, S. Imes, A. Rabinovitch, J. F. Elliott, D. Bigam, N. M. Kneteman, et al. 2001. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 50: 710-719.
4. Sutherland, D. E., R. Sibley, X. Z. Xu, A. Michael, A. M. Srikanta, F. Taub, J. Najarian, and F. C. Goetz. 1984. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans. Assoc. Am. Phys. 97: 80-87.
5. Morel, P. A., J. S. Dorman, J. A. Todd, H. O. McDevitt, and M. Trucco. 1988. Aspartic acid at position 57 of the HLA-DQ β chain protects against type I diabetes: a family study. Proc. Natl. Acad. Sci. USA 85: 8111-8115.
6. Achenbach, P., E. Bonifacio, K. Koczwara, and A. G. Ziegler. 2005. Natural history of type 1 diabetes. Diabetes 54 (Suppl. 2): S25-S31.
7. Atkinson, M. A., and E. H. Leiter. 1999. The NOD mouse model of type 1 diabetes: as good as it gets? Nat. Med. 5: 601-604.
8. Hattori, M., J. B. Buse, R. A. Jackson, L. Glimcher, M. E. Dorf, M. Minami, S. Makino, K. Moriwaki, H. Kuzuya, H. Imura, and et al. 1986. The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex. Science 231: 733-735.
9. g7 MHC class II molecule linked to murine diabetes is a promiscuous peptide binder. J. Immunol. 165: 3214-3225.
10. Ettinger, R. A., A. W. Liu, G. T. Nepom, and W. W. Kwok. 1998. Exceptional stability of the HLA-DQA1*0102/DQB1*0602 αβ protein dimer, the class II MHC molecule associated with protection from insulin-dependent diabetes mellitus. J. Immunol. 161: 6439-6445.
11. Corper, A. L., T. Stratmann, V. Apostolopoulos, C. A. Scott, K. C. Garcia, A. S. Kang, I. A. Wilson, and L. Teyton. 2000. A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science 288: 505-511.
12. Acha-Orbea, H., and H. O. McDevitt. 1987. The first external domain of the nonobese diabetic mouse class II I-A β chain is unique. Proc. Natl. Acad. Sci. USA 84: 2435-2439.
13. Singer, S. M., R. Tisch, X. Yang, and H. O. McDevitt. 1993. An Abd transgene prevents diabetes in nonobese diabetic mice by inducing regulatory T cells. Proc. Natl. Acad. Sci. USA 90: 9566-9570.
14. Lund, T., L. O'Reilly, P. Hutchings, O. Kanagawa, E. Simpson, R. Gravely, P. Chandler, J. Dyson, J. K. Picard, A. Edwards, et al. 1990. Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A β-chain or normal I-E α-chain. Nature 345: 727-729.
15. Singer, S. M., R. Tisch, X. D. Yang, and H. O. McDevitt. 1993. An Abd transgene prevents diabetes in nonobese diabetic mice by inducing regulatory T cells. Proc. Natl. Acad. Sci. USA 90: 9566-9570.
16. Slattery, R. M., L. Kjer-Nielsen, J. Allison, B. Charlton, T. E. Mandel, and J. F. Miller. 1990. Prevention of diabetes in non-obese diabetic I-Ak transgenic mice. Nature 345: 724-726.
17. Reich, E. P., R. S. Sherwin, O. Kanagawa, and C. A. Janeway, Jr. 1989. An explanation for the protective effect of the MHC class II I-E molecule in murine diabetes. Nature 341: 326-328.
18. Uehira, M., M. Uno, T. Kurner, H. Kikutani, K. Mori, T. Inomoto, T. Uede, J. Miyazaki, H. Nishimoto, T. Kishimoto, et al. 1989. Development of autoimmune insulitis is prevented in E α d but not in A β k NOD transgenic mice. Int. Immunol. 1: 209-213.
19. Beilhack, G. F., Y. C. Scheffold, I. L. Weissman, C. Taylor, L. Jerabek, M. J. Burge, M. A. Masek, and J. A. Shizuru. 2003. Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Diabetes 52: 59-68.
20. Li, H., C. L. Kaufman, S. S. Boggs, P. C. Johnson, K. D. Patrene, and S. T. Ildstad. 1996. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice. J. Immunol. 156: 380-388.
21. Seung, E., N. Iwakoshi, B. A. Woda, T. G. Markees, J. P. Mordes, A. A. Rossini, and D. L. Greiner. 2000. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versushost disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood 95: 2175-2182.
22. Daly, A., S. McAfee, B. Dey, C. Colby, L. Schulte, B. Yeap, R. Sackstein, N. J. Tarbell, D. Sachs, M. Sykes, and T. R. Spitzer. 2003. Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol. Blood Marrow Transplant. 9: 373-382.
23. Blazar, B. R., and W. J. Murphy. 2005. Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). Philos. Trans. R. Soc. London B 360: 1747-1767.
24. Parkman, R., and K. I. Weinberg. 1997. Immunological reconstitution following bone marrow transplantation. Immunol. Rev. 157: 73-78.
25. Williams, M. A., A. B. Adams, M. B. Walsh, N. Shirasugi, T. M. Onami, T. C. Pearson, R. Ahmed, and C. P. Larsen. 2003. Primary and secondary immunocompetence in mixed allogeneic chimeras. J. Immunol. 170: 2382-2389.
26. Clift, R. A., and R. Storb. 1987. Histoincompatible bone marrow transplants in humans. Annu. Rev. Immunol. 5: 43-64.
27. Welniak, L. A., B. R. Blazar, and W. J. Murphy. 2007. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu. Rev. Immunol. 25: 139-170.
28. Bagley, J., C. Tian, D. H. Sachs, and J. Iacomini. 2002. Induction of T-cell tolerance to an MHC class I alloantigen by gene therapy. Blood 99: 4394-4399.
29. Bracy, J. L., and J. Iacomini. 2000. Induction of B-cell tolerance by retroviral gene therapy. Blood 96: 3008-3015.
30. Kang, E. S., and J. Iacomini. 2002. Induction of central deletional T cell tolerance by gene therapy. J. Immunol. 169: 1930-1935.
31. Tian, C., J. Bagley, N. Cretin, N. Seth, K. W. Wucherpfennig, and J. Iacomini. 2004. Prevention of type 1 diabetes by gene therapy. J. Clin. Invest. 114: 969-978.
32. Forman, D., E. S. Kang, C. Tian, J. Paez-Cortez, and J. Iacomini. 2006. Induction of alloreactive CD4 T cell tolerance in molecular chimeras: a possible role for regulatory T cells. J. Immunol. 176: 3410-3416.
33. Tian, C., J. Bagley, and J. Iacomini. 2005. Preventing autoimmune diabetes through gene therapy. Disc. Med. 5: 186-190.
34. Sharpe, A. H., E. J. Wherry, R. Ahmed, and G. J. Freeman. 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8: 239-245.
35. Ansari, M. J., A. D. Salama, T. Chitnis, R. N. Smith, H. Yagita, H. Akiba, T. Yamazaki, M. Azuma, H. Iwai, S. J. Khoury, et al. 2003. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198: 63-69.
36. Tsushima, F, H. Iwai, N. Otsuki, M. Abe, S. Hirose, T. Yamazaki, H. Akiba, II Yagita, Y. Takahashi, K. Omura, et al. 2003. Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. Eur. J. Immunol. 33: 2773-2782.
37. Makhlouf, L., A. Yamada, T. Ito, R. Abdi, M. J. Ansari, C. Q. Khuong, H. J. Winn, H. Auchincloss, Jr., and M. H. Sayegh. 2003. Allorecognition and effector pathways of islet allograft rejection in normal versus nonobese diabetic mice. J. Am. Soc. Nephrol. 14: 2168-2175.
38. Hausmann, D. H., B. Yu, S. Hausmann, and K. W. Wucherpfennig. 1999. pH-dependent peptide binding properties of the type I diabetes-associated I-Ag7 molecule: rapid release of CLIP at an endosomal pH. J. Exp. Med. 189: 1723-1734.
39. Chao, C. C., H. K. Sytwu, E. L. Chen, J. Toma, and H. O. McDevitt. 1999. The role of MHC class II molecules in susceptibility to type I diabetes: identification of peptide epitopes and characterization of the T cell repertoire. Proc. Natl. Acad. Sci. USA 96: 9299-9304.
40. Dantal, J., M. Hourmant, D. Cantarovich, M. Giral, G. Blancho, B. Dreno, and J. P. Soulillou. 1998. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 351: 623-628.
41. Newstead, C. G. 1998. Assessment of risk of cancer after renal transplantation. Lancet. 351: 610-611.
42. Orloff, M. S., E. M. DeMara, M. L. Coppage, N. Leong, M. A. Fallon, J. Sickel, X. J. Zuo, J. Prehn, and S. C. Jordan. 1995. Prevention of chronic rejection and graft arteriosclerosis by tolerance induction. Transplantation 59: 282-288.
43. Brocker, T., M. Riedinger, and K. Karjalainen. 1997. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J. Exp. Med. 185: 541-550.
44. Jenkinson, E. J., G. Anderson, and J. J. Owen. 1992. Studies on T cell maturation on defined thymic stromal cell populations in vitro. J. Exp. Med. 176: 845-853.
45. Bagley, J., C. Tian, D. H. Sachs, and J. Iacomini. 2002. T cells mediate resistance to genetically modified bone marrow in lethally irradiated recipients. Transplantation 74: 1454-1460.
46. You, S., M. Belghith, S. Cobbold, M. A. Alyanakian, C. Gouarin, S. Barriot, C. Garcia, H. Waldmann, J. F. Bach, and L. Chatenoud. 2005. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 54: 1415-1422.
47. Tian, C., J. Bagley, and J. Iacomini. 2006. Persistence of antigen is required to maintain transplantation tolerance induced by genetic modification of bone marrow stem cells. Am. J. Transplant. 6: 2202-2207.
48. Chang, Y., and G. J. Prud'homme. 1999. Intramuscular administration of expression plasmids encoding interferon-γ receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity. J. Gene Med. 1: 415-423.
49. Feili-Hariri, M., D. H. Falkner, A. Gambotto, G. D. Papworth, S. C. Watkins, P. D. Robbins, and P. A. Morel. 2003. Dendritic cells transduced to express interleukin-4 prevent diabetes in nonobese diabetic mice with advanced insulitis. Hum. Gene Ther. 14: 13-23.
50. Goudy, K., S. Song, C. Wasserfall, Y. C. Zhang, M. Kapturczak, A. Muir, M. Powers, M. Scott-Jorgensen, M. Campbell-Thompson, J. M. Crawford, et al. 2001. Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. Proc. Natl. Acad. Sci. USA 98: 13913-13918.
51. Hayashi, T., Y. Yasutomi, K. Hasegawa, Y. Sasaki, and T. Onodera. 2003. Interleukin-4-expressing plasmid DNA inhibits reovirus type-2-triggered autoimmune insulitis in DBA/1 J suckling mice. Int. J. Exp. Pathol. 84: 101-106.
52. Ko, K. S., M. Lee, J. J. Koh, and S. W. Kim. 2001. Combined administration of plasmids encoding IL-4 and IL-10 prevents the development of autoimmune diabetes in nonobese diabetic mice. Mol. Ther. 4: 313-316.
53. Koh, J. J., K. S. Ko, M. Lee, S. Han, J. S. Park, and S. W. Kim. 2000. Degradable polymeric carrier for the delivery of IL-10 plasmid DNA to prevent autoimmune insulitis of NOD mice. Gene Ther. 7: 2099-2104.
54. Lee, M., K. S. Ko, S. Oh, and S. W. Kim. 2003. Prevention of autoimmune insulitis by delivery of a chimeric plasmid encoding interleukin-4 and interleukin-10. J. Control Release 88: 333-342.
55. Lu, L., W. C. Lee, T. Takayama, S. Qian, A. Gambotto, P. D. Robbins, and A. W. Thomson. 1999. Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-β, and CTLA4Ig). J. Leukocyte Biol. 66: 293-296.
56. Moritani, M., K. Yoshimoto, S. Ii, M. Kondo, H. Iwahana, T. Yamaoka, T. Sano, N. Nakano, H. Kikutani, and M. Itakura. 1996. Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. A gene therapy model for autoimmune diabetes. J. Clin. Invest. 98: 1851-1859.
57. Piccirillo, C. A., Y. Chang, and G. J. Prud'homme. 1998. TGF-β1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice. J. Immunol. 161: 3950-3956.
58. Prud'homme, G. J., and Y. Chang. 1999. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-γ receptor/IgG1 fusion protein. Gene Ther. 6: 771-777.
59. Yang, Z., M. Chen, R. Wu, L. B. Fialkow, J. S. Bromberg, M. McDuffie, A. Naji, and J. L. Nadler. 2002. Suppression of autoimmune diabetes by viral IL-10 gene transfer. J. Immunol. 168: 6479-6485.
60. Zipris, D., and E. Karnieli. 2002. A single treatment with IL-4 via retrovirally transduced lymphocytes partially protects against diabetes in BioBreeding (BB) rats. JOP 3: 76-82.
61. Zhang, Y. C., A. Pileggi, A. Agarwal, R. D. Molano, M. Powers, T. Brusko, C. Wasserfall, K. Goudy, E. Zahr, R. Poggioli, et al. 2003. Adeno-associated virus-mediated IL-10 gene therapy inhibits diabetes recurrence in syngeneic islet cell transplantation of NOD mice. Diabetes 52: 708-716.
62. White, S. A., M. L. Nicholson, and B. J. Hering. 2000. Can islet cell transplantation treat diabetes? BMJ 321: 651-652.
63. Wells, A. D., X. C. Li, Y. Li, M. C. Walsh, X. X. Zheng, Z. Wu, G. Nunez, A. Tang, M. Sayegh, W. W. Hancock, et al. 1999. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5: 1303-1307.
64. Li, X. C., A. D. Wells, T. B. Strom, and L. A. Turka. 2000. The role of T cell apoptosis in transplantation tolerance. Curr. Opin. Immunol. 12: 522-527.